GlassScriptPhysician profile
Tony Dicken
NPI 1124620364
$6,401.46
in general payments reported to CMS, 2019-2025
25 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,465 · 2022: $1,098 · 2023: $1,329 · 2024: $1,237 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,838.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,393.96 | 2021-2025 | |
| Alkermes, INC. | $545.11 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $479.22 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $355.17 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $314.61 | 2021-2025 | Spravato |
| Braeburn INC. | $300.90 | 2023-2025 | Brixadi |
| Lundbeck LLC | $276.35 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $258.67 | 2021-2025 | Rexulti, Abilify Maintena |
| Almatica Pharma LLC | $222.92 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $213.18 | 2021-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $163.49 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $161.67 | 2021-2025 | |
| Indivior INC. | $122.00 | 2021-2025 | Sublocade |
| Corium, LLC | $106.99 | 2023-2024 | Azstarys |
| Bausch Health US, LLC | $96.11 | 2022-2025 | Aplenzin, Wellbutrin |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $82.92 | 2022-2024 | Qelbree |
| Vanda Pharmaceuticals INC. | $70.77 | 2021-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $53.93 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $47.17 | 2023 | Quviviq |
| Eisai INC. | $44.22 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $30.11 | 2021 | |
| Neuronetics, INC. | $20.78 | 2023 | Neurostar Tms Therapy System |
| Noven Therapeutics, LLC | $15.00 | 2022 | |
| Neos Therapeutics, LP | $14.49 | 2022 | |
| Uswm, LLC | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Dicken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.